MediWound Ltd. MDWD

Healthcare SIC 2833 - Medicinal Chemicals & Botanical Products NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $17.0M$20.2M$18.7M$26.5M$23.8M$21.8M$31.8M$3.4M$2.5M$1.6M
Operating income -$25.3M-$19.4M-$15.3M-$8.3M-$11.2M-$8.8M$4.5M-$4.0M-$13.7M-$20.2M
Net income -$23.9M-$30.2M-$6.7M-$19.6M-$13.6M-$9.2M$5.0M-$1.1M-$22.1M-$18.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $86.3M$73.5M$66.5M$50.0M$19.7M$31.1M$40.6M$35.3M$44.1M$35.8M
Total equity $43.6M$31.2M$31.6M$10.9M-$4.6M$7.3M$15.2M$9.0M$9.4M$7.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-000749.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -20M 0 20M 40M Revenue, FY2016: 1.6M Net income, FY2016: -18.9M Revenue, FY2017: 2.5M Net income, FY2017: -22.1M Revenue, FY2018: 3.4M Net income, FY2018: -1.1M Revenue, FY2019: 31.8M Net income, FY2019: 5M Revenue, FY2020: 21.8M Net income, FY2020: -9.2M Revenue, FY2021: 23.8M Net income, FY2021: -13.6M Revenue, FY2022: 26.5M Net income, FY2022: -19.6M Revenue, FY2023: 18.7M Net income, FY2023: -6.7M Revenue, FY2024: 20.2M Net income, FY2024: -30.2M Revenue, FY2025: 17M Net income, FY2025: -23.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.6M $2.5M $3.4M $31.8M $21.8M $23.8M $26.5M $18.7M $20.2M $17.0M
Gross profit — — — — — — — — — —
Net income -$18.9M -$22.1M -$1.1M $5.0M -$9.2M -$13.6M -$19.6M -$6.7M -$30.2M -$23.9M

Others in SIC 2833

TickerCompanyMarket capP/ERevenue growth
DFTX Definium Therapeutics, Inc. $4.79B — —
TRLV Trulieve Cannabis Corp. $2.01B — -0.4%
CRON Cronos Group Inc. $1.23B — 24.6%
TLRY Tilray Brands, Inc. $382.7M — 11.5%
CGC Canopy Growth Corp $285.9M — —
USNA USANA HEALTH SCIENCES INC $257.9M 24.1x 8.3%
NAGE Niagen Bioscience, Inc. $192.3M 12.2x 29.9%
FTLF FITLIFE BRANDS, INC. $78.4M 13.3x 26.4%